Larvol Delta - Apnimed-Announces-Positive-Phase-2-Study-APC003-Data-Demonstrating-DurabilityofEffect-and-Improved-QualityofLife-in-Patients-with-Obstructive-Sleep-Apnea-After-Investigational-AD109-Treatment

aroxybutynin/atomoxetine (AD109) - Apnimed

https://www.businesswire.com/news/home/20211013005306/en/Apnimed-Announces-Positive-Phase-2-Study-APC-003-Data-Demonstrating-Durability-of-Effect-and-Improved-Quality-of-Life-in-Patients-with-Obstructive-Sleep-Apnea-After-Investigational-AD109-Treatment

Oct 13, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next